Tianjin Tianyao Pharmaceuticals Co., Ltd.

Shanghai Stock Exchange 600488.SS

Tianjin Tianyao Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: 45.04%

Tianjin Tianyao Pharmaceuticals Co., Ltd. Gross Profit Margin is 45.04% for the year ending December 31, 2023, a -8.22% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Tianjin Tianyao Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 49.07%, a 3.02% change year over year.
Tianjin Tianyao Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 47.63%, a 3.54% change year over year.
Tianjin Tianyao Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 46.01%, a -3.92% change year over year.
Tianjin Tianyao Pharmaceuticals Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 47.88%, a -4.61% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 600488.SS

Tianjin Tianyao Pharmaceuticals Co., Ltd.

CEO	Mr. Shuxiang Li
IPO Date	June 18, 2001
Location	China
Headquarters	No. 19, Xinye 9th Street
Employees	2,678
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Chemicals & Advanced Materials Drugstores & Retail Pharmacies Personal Care Petrochemicals Plastics

Description

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.

Key trends

Past 5 years